Tarsier Pharma’s stalled IPO process underpins the 96.9% market-implied odds of no listing before September 2026. The Israel-based Phase 3 ophthalmic biotech filed its F-1 in April 2026 and updated terms in May–July for a modest $45–50 million NYSE American offering of roughly 5.5 million shares at $8–10, yet successive F-1/A amendments through mid-July produced no pricing date or listing. This pattern aligns with historical base rates for delayed micro-cap biotechs lacking broad underwriter support and pre-revenue clinical assets. A last-minute institutional anchor or accelerated window before the August 31 resolution deadline remains possible but faces a highly compressed timeline that leaves little margin for completion.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · ActualizadoNo salida a bolsa antes de septiembre de 2026 97.0%
$300M-$350M <1%
$350M-$400M <1%
$400M-$450M <1%
$17,980 Vol.
$17,980 Vol.
31 ago 2026
<$250M
<1%
$250M-$300M
<1%
$300M-$350M
<1%
$350M-$400M
<1%
$400M-$450M
<1%
>$450M
<1%
No salida a bolsa antes de septiembre de 2026
97%
No salida a bolsa antes de septiembre de 2026 97.0%
$300M-$350M <1%
$350M-$400M <1%
$400M-$450M <1%
$17,980 Vol.
$17,980 Vol.
31 ago 2026
<$250M
$1,152 Vol.
<1%
$250M-$300M
$1,113 Vol.
<1%
$300M-$350M
$1,642 Vol.
<1%
$350M-$400M
$837 Vol.
<1%
$400M-$450M
$629 Vol.
<1%
>$450M
$1,068 Vol.
<1%
No salida a bolsa antes de septiembre de 2026
$11,539 Vol.
97%
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Tarsier Pharma’s stalled IPO process underpins the 96.9% market-implied odds of no listing before September 2026. The Israel-based Phase 3 ophthalmic biotech filed its F-1 in April 2026 and updated terms in May–July for a modest $45–50 million NYSE American offering of roughly 5.5 million shares at $8–10, yet successive F-1/A amendments through mid-July produced no pricing date or listing. This pattern aligns with historical base rates for delayed micro-cap biotechs lacking broad underwriter support and pre-revenue clinical assets. A last-minute institutional anchor or accelerated window before the August 31 resolution deadline remains possible but faces a highly compressed timeline that leaves little margin for completion.
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Mercado abierto: Jul 7, 2026, 9:12 AM ET
Volumen
$17,980Fecha de finalización
1 sep 2026Mercado abierto
Jul 7, 2026, 9:12 AM ETResolver
0x69c47De9D...This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Tarsier Pharma’s stalled IPO process underpins the 96.9% market-implied odds of no listing before September 2026. The Israel-based Phase 3 ophthalmic biotech filed its F-1 in April 2026 and updated terms in May–July for a modest $45–50 million NYSE American offering of roughly 5.5 million shares at $8–10, yet successive F-1/A amendments through mid-July produced no pricing date or listing. This pattern aligns with historical base rates for delayed micro-cap biotechs lacking broad underwriter support and pre-revenue clinical assets. A last-minute institutional anchor or accelerated window before the August 31 resolution deadline remains possible but faces a highly compressed timeline that leaves little margin for completion.
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Volumen
$17,980Fecha de finalización
1 sep 2026Mercado abierto
Jul 7, 2026, 9:12 AM ETResolver
0x69c47De9D...Tarsier Pharma’s stalled IPO process underpins the 96.9% market-implied odds of no listing before September 2026. The Israel-based Phase 3 ophthalmic biotech filed its F-1 in April 2026 and updated terms in May–July for a modest $45–50 million NYSE American offering of roughly 5.5 million shares at $8–10, yet successive F-1/A amendments through mid-July produced no pricing date or listing. This pattern aligns with historical base rates for delayed micro-cap biotechs lacking broad underwriter support and pre-revenue clinical assets. A last-minute institutional anchor or accelerated window before the August 31 resolution deadline remains possible but faces a highly compressed timeline that leaves little margin for completion.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · ActualizadoRelacionado
¿CopperTech Metals no saldrá a bolsa antes de septiembre de 2026?
99%
Sí
¿Tendrá Discord una capitalización de mercado entre $11 mil millones y $14 mil millones al cierre del mercado en el día de su OPI antes del 31 de diciembre de 2027?
28%
Sí
¿Databricks no saldrá a bolsa antes del 31 de diciembre de 2027?
64%
Sí
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes